$FUL

H.B. Fuller's board rejected an unsolicited bid for its BAS segment, citing a valuation below market precedent and lack of financing details. The board highlighted BAS's 6% organic growth and 10% EBITDA improvement, noting its importance for future earnings. The board also cited operational integration challenges and reaffirmed its strategic priorities, including the Advanced Medical Solutions acquisition and Project Quantum Leap.

H.B. Fuller Co. (NYSE:FUL) shares were unchanged in premarket trading after its board rejected Ancora Holdings Group's $1.2 billion bid for its building adhesives unit, citing undervaluation and lack of growth potential consideration. Ancora criticized the rejection as irrational and emphasized its ability to finance a higher offer. The bid aimed to help H.B. Fuller reduce debt and focus on integrating Advanced Medical Solutions Group Plc.

H.B. Fuller (NYSE:FUL) said Advanced Medical Solutions Group plc (LSE:AMS) shareholders approved the proposed cash acquisition of AMS. The approval is a milestone toward closing, which H.B. Fuller expects by year end, subject to remaining conditions and regulatory approvals. H.B. Fuller reported 2025 revenue of $3.5B.

Weaver Nathan D. (Exec VP, Business Transform.) sold 9,561 shares of FULLER H B CO (FUL) at $62.06 ($0.59M total) on 2026-08-11.

H.B. Fuller shares fell about 1.3% after activist Ancora Holdings disclosed a formal cash offer to buy the company’s Building Adhesive Solutions segment for $1.1 billion to $1.2 billion, escalating a dispute over strategy. Separately, AMS shareholders approved H.B. Fuller’s recommended cash acquisition of Advanced Medical Solutions Group with 84.23% voting in favor. Macro CPI was in line.

Ancora Holdings Group proposed, via a letter to H.B. Fuller’s board, to buy H.B. Fuller’s Building Adhesive Solutions unit for $1.1 billion to $1.2 billion in cash, per Bloomberg. Ancora said the sale could reduce H.B. Fuller’s debt and help it focus on integrating Advanced Medical Solutions Group Plc. The deal is subject to approvals and due diligence.

FULLER H B CO (FUL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex_989568.htm EXHIBIT 10.1 ex_989568.htm Exhibit 10.1 This AMENDMENT NO. 3, dated as of July 17, 2026 (this “ Amendment ”), is made and entered into by and among H.B. FULLER COMPANY, a Minnesota corporation (the “ Borrower ”), the Subsidiary Guarantors listed on the sig

Advanced Medical Solutions Group PLC (AMS) published the scheme document for a recommended cash acquisition of all AMS shares by Bidco, a wholly owned subsidiary of H.B. Fuller. The deal follows a possible offer announcement in May 2026 and requires court and shareholder approvals, with meetings set for 12 Aug 2026. The scheme is expected to become effective in Q3 or Q4 2026.

FULLER H B CO (FUL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 5 ex_981230.htm EXHIBIT 10.2 ex_981230.htm Exhibit 10.2 SECURED BRIDGE CREDIT AGREEMENT dated as of June 25, 2026, among H.B. FULLER COMPANY The Lenders Party Hereto and GOLDMAN SACHS BANK USA, as Administrative Agent GOLDMAN SACHS BANK USA, as Sole Lead Arranger and Book

FULLER H B CO (FUL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_980922.htm EXHIBIT 99.1 ex_980922.htm Worldwide Headquarters 1200 Willow Lake Boulevard St. Paul, Minnesota 55110-5101 Exhibit 99.1 Scott Jensen Investor Relations Contact investors@hbfuller.com NEWS June 24, 2026 H.B. Fuller Reports Second Quarter 2026 Results Repor